

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - What NHS-Galleri taught us—and what it didn’t
- Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital




















